B/BE/25/BVW3 - Information sheet for the public (prepared by the notifier)

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B